This document summarizes the results of a survey of spinal cord stimulation procedures in Denmark between 2014-2015 from a national neuromodulation database. It found that the most common indications for spinal cord stimulation were radicular pain after spine surgery and peripheral nerve damage. The median patient age was 48.8 years old and symptom duration was 54.8 months. Most patients reported severe pain, with median 7-day pain averages of 7 out of 10 and worst pain of 9.8 out of 10. The most common implantable pulse generators were from Medtronic and St. Jude Medical and the most common leads were from Medtronic and St. Jude Medical.

1. Amputation, phantom pain
3
Amputation, stump pain
1
Angina pectoris
2
Back pain after spinal surgery
14
Back pain, NO previous spine
surgery
2
CRPS I
3
CRPS II
5
Medullar lesion, incomplete
1
Neuropathy, diabetic
3
Neuropathy, other
5
Peripheral nerve damage, plexus injury
1
Peripheral nerve damage
13
Radicular pain after spine
surgery
36
Radicular pain, NO previous
spine surgery
2
Unknown
13
PRIMARY INDICATIONS
Kaare Meier, MD PhD1,2,3, Christian Scherer, MD4,5, Christina Rosenlund, MD4, Helga A. Gulisano, MD6, Thomas P. Enggaard, MD PhD7,
Lisette M. Willumsen, MD8, Anne Lene H. Knudsen, RN1, Mattias Rasmusson, MSc3,9, Jens Christian Sørensen, MD PhD DMSc1,3
Reference:
Meier K. et al: The Aarhus Neuromodulation Database.
Neuromodulation. 2013 Nov-Dec;16(6):506-13.
A DANISH SURVEY OF SPINAL CORD STIMULATION BASELINE DATA:
FIRST RESULTS FROM A NATIONAL NEUROMODULATION DATABASE
1Dept. of Neurosurgery, 2Dept. of Anesthesiology, Aarhus University Hospital, 3Neurizon ApS, Aarhus, 4Dept. of Neurosurgery, 5Dept. of Anesthesiology, Odense University Hospital, Odense, 6Dept.
of Neurosurgery, Aalborg University Hospital, Aalborg, 7Multidisciplinary Pain Centre, 8Dept. of Neurosurgery, Rigshospitalet, Copenhagen, Denmark, 9Evibase LLC, Boston, MA, United States
WHY?
Evidence for the efficacy of spinal cord
stimulation (SCS) and dorsal root ganglion
stimulation (DRG) is accumulating thanks to an
increasing number of published data from
randomized controlled trials.
Much less is known about the application of SCS
in everyday clinical practice outside a controlled
study setting: Who gets implanted and on what
indications? What is the choice of implant? How
do the treatments perform?
WHAT?
Data on all patients receiving their first SCS or
DRG implant(s) between 1 January 2014 and 30
May 2015 in Denmark was retrieved from the
Neurizon Neuromodulation Database.
For this survey, only baseline patient data and
selected procedure data were analyzed.
The database is in routine use at all the four
centers performing SCS and DRG in Denmark.
HOW?
The Neurizon Neuromodulation Database is an
internet-based, generic, module-oriented,
publicly available database.
The numerous modules cover detailed patient
characteristics and core treatment parameters,
including procedure-related details and
complications.
It also features recording of key success
parameters for follow-up of the treatment such as
pain intensity, work status, and quality of life.
Conflict of interest:
Dr. Meier and Prof. Sørensen have received research support and lecture fees from
St. Jude Medical.
Dr. Meier, Prof. Sørensen, and Mr. Rasmusson are proprietors of Neurizon.
NEURIZON NEUROMODULATION DATABASE
Based mainly on drop-down menus, the Neurizon Neuromodulation Database is quick and easy to use, and it
covers all relevant parameters for full patient management and for continuous monitoring and research.
It is web-based, programmed using industry standards to ensure scalability and performance, and hosted on
a commercial server with full traffic encryption.
The Neurizon Neuromodulation Database is intended for international collaboration, and the Swiss
Neuromodulation Society recently joined the network.
Our other colleagues in the field of neuromodulation are invited to use the database in their own practice as
a free clinical tool. Independent mirrors of the database can be set up, keeping data local and confident.
For more information, please contact: neuro@kaare.org
Abstract ID: 2220737
International Neuromodulation Society, Montreal 2015
PATIENT CHARACTERISTICS
Boston Scientific
Precision Plus 2.0
5
Boston Scientific
Precision Spectra
1
Medtronic
PrimeAdvanced
12
Medtronic
PrimeAdvanced SS
21
St. Jude Medical Eon
13
St. Jude Medical Eon
Mini
8
St. Jude Medical EonC
12
Spinal Modulation Axium
6
IPGS
Boston Scientific Linear
Wide 3-4
6
Boston Scientific Linear
Wide 3-6
2
Medtronic Octad
stogard
7
Medtronic Octad sub-
compact
1
Medtronic Pisces Quad
compact
1
Medtronic Pisces Quad
plus
4
Medtronic Vectris SS
27
Medtronic other
2
St. Jude Medical Octrode
23
St. Jude Medical S8
Lamitrode
20
Spinal Modulation Axium
9
Unknown
2
LEADS
25% Median 75%
Patient
age (years)
40.9 48.8 55.3
n = 82
Symptom
duration (months)
34.7 54.8 87.3
n = 80
7-day pain
average (NRS)
6 7 8
n = 53
7-day worst
pain (NRS)
8 9.8 10
n = 54
Male
44
Female
38
Employed
10%
Flexijob / light duties
23%
Self-employed
2%
Student
2%
Sickness benefit
10%
Unemployment benefit 2%
Social security
8%
Disability pensioner
23%
Pensioner 18%
Other 2%
WORK STATUS, n = 51